Cell Therapy Firm Kyverna Eyes $200M IPO As Pipeline Builds

By Tom Zanki (February 1, 2024, 4:37 PM EST) -- Autoimmune diseases-focused drug developer Kyverna Therapeutics Inc. on Thursday unveiled a price range for an estimated $200 million initial public offering, guided by Paul Hastings LLP and underwriters counsel Covington & Burling LLP, joining an IPO pipeline that has become more promising for life sciences firms....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.

A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!